Rocket Pharmaceuticals, Inc. Employee-related Liabilities, Current
Rocket Pharmaceuticals, Inc. (RCKT) had Employee-related Liabilities, Current of $7.07 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-08-10
- 2026-06-30: Employee-related Liabilities, Current $7.07M.
- 2026-03-31: Employee-related Liabilities, Current $5.24M.
- 2025-12-31: Employee-related Liabilities, Current $12.29M.
- 2025-09-30: Employee-related Liabilities, Current $11.43M.
| Period end | Employee-related Liabilities, Current | Employee-related Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.07M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $5.24M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $12.29M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $11.43M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $8.05M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $7.07M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $11.94M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $10.32M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $7.29M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $4.19M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $9.93M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $8.36M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $6.01M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $4.20M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $10.01M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $4.79M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $3.01M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.48M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $4.53M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $3.81M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $3.12M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $6.19M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $4.88M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $2.80M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $2.07M 10-Q · filed 2020-08-05 | |
| 2019-12-31 | $2.59M 10-K · filed 2021-03-01 | |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $128.00K 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $50.00K 10-Q · filed 2018-08-14 | $793.00K 10-K · filed 2018-03-07 |
| 2017-09-30 | $706.00K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $1.10M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $1.22M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $1.63M 10-K · filed 2018-03-07 | $2.17M 10-K · filed 2017-03-16 |
| 2016-09-30 | $1.33M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $854.00K 10-Q · filed 2016-08-10 | |
| 2016-03-31 | $590.00K 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $999.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $692.00K 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $563.00K 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $345.00K 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $293.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |